Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy

Related Experiment Video

Updated: Aug 3, 2025

Author Spotlight: Advantages of Pressure-Volume Loop Measurement Method in Cardiovascular Research
04:27

Author Spotlight: Advantages of Pressure-Volume Loop Measurement Method in Cardiovascular Research

Published on: January 12, 2024

557

Changlin Zhen1,2, Xunxun Wu3, Jing Zhang1,2

  • 1Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing, China.

Frontiers in Pharmacology
|April 10, 2023
PubMed

Insights

Ganoderma lucidum polysaccharides (GLPs) effectively treat pathological cardiac hypertrophy by inhibiting key genes involved in hypertrophy and fibrosis. This natural compound activates the PPARγ pathway, offering potential for heart failure treatment.

Area of Science:

  • Cardiovascular Biology
  • Pharmacology
  • Natural Products Research

Background:

  • Pathological cardiac hypertrophy is a significant risk factor for cardiovascular disease.
  • Current drug therapies for reversing cardiac hypertrophy and restoring heart function are limited.
  • Ganoderma lucidum polysaccharides (GLPs) are bioactive compounds from Ganoderma lucidum with diverse pharmacological effects.

Purpose of the Study:

  • To investigate the therapeutic potential of GLPs in ameliorating cardiac hypertrophy.
  • To elucidate the molecular mechanisms underlying the cardioprotective effects of GLPs.

Main Methods:

  • Cardiac hypertrophy was induced in mice via transverse aortic constriction (TAC).
  • Cardiomyocyte hypertrophy was induced by Angiotensin II (Ang II) in vitro.
  • Gene expression analysis focused on hypertrophic and fibrotic markers, including the PPARγ/PGC-1α pathway.

Main Results:

  • GLPs demonstrated efficacy in ameliorating Ang II-induced cardiomyocyte hypertrophy in vitro.
  • GLPs significantly attenuated pressure overload-induced cardiac hypertrophy in vivo.
  • GLPs downregulated mRNA levels of hypertrophic and fibrotic markers, indicating inhibition via the PPARγ/PGC-1α pathway.

Conclusions:

  • GLPs inhibit pathological cardiac hypertrophy by downregulating key genes associated with hypertrophy and fibrosis.
  • Activation of the PPARγ pathway by GLPs plays a crucial role in attenuating pressure overload-induced cardiac hypertrophy.
  • These findings support the potential use of GLPs as a therapeutic agent for pathological myocardial hypertrophy and heart failure.

Keywords:
GLPsPGC-1αPPARγcardiac hypertrophyheart function

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

232
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

807

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
474
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
434
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
19
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
647
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
20